Brokerages Set Haleon plc (LON:HLN) PT at GBX 407.83

Haleon plc (LON:HLN) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 407.83.

Several equities research analysts recently commented on HLN shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a research report on Friday, October 31st. Berenberg Bank boosted their price target on Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. upped their price objective on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a research report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft dropped their target price on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 450 target price on shares of Haleon in a research note on Wednesday, January 21st.

Haleon Price Performance

Shares of HLN stock opened at GBX 370.10 on Thursday. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. Haleon has a 12-month low of GBX 325.10 and a 12-month high of GBX 419.50. The firm has a fifty day moving average of GBX 369.23 and a 200-day moving average of GBX 359.44. The firm has a market capitalization of £32.96 billion, a price-to-earnings ratio of 22.16, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.